goodrx novo nordisk - Search News

News

Novo Nordisk Adds Ozempic to Direct-to-Consumer Offerings

Barron's on MSN · 19h

Novo Nordisk Adds Ozempic to Direct-to-Consumer Offerings, at $499 Per Month. Why GoodRx Stock Spikes.

Shares of GoodRx were spiking 35% on Monday. The announcement followed news from Novo Nordisk that the Food and Drug Administration had approved Wegovy for treatment of a serious form of liver disease. Shares of the Danish drugmaker were rising 4.9% in U.S. trading.

Reuters on MSN · 17h

Novo Nordisk offers Ozempic at $499 per month to eligible US cash-paying customers

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients with type 2 diabetes in the U.S. via its own pharmacy, a tie-up with telehealth service GoodRx and other platforms.

The Pharma Letter · 1h

GoodRx and Novo Nordisk unveil $499 monthly offer for Ozempic and Wegovy

GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy (semaglutide) available to eligible self-paying patients for $499 per month.

18hon MSN

Novo Nordisk to sell weight-loss drug for $499 to eligible customers

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

14hon MSN

US patients can now get Ozempic for half price if they can pay cash

Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results